$IMTL – Recent Acquisition of ImageProtect Proves Fruitful – Generating Strong Revenues Through Market Niche of Digital Image Copyright Enforcement

Tuesday, January 31, 2017

$IMTL – Recent Acquisition of ImageProtect Proves Fruitful – Generating Strong Revenues Through Market Niche of Digital Image Copyright Enforcement

On March 15^th, 2016, (OTCMKTS: IMTL), former Image Technology Labs, announced the completion of the merger with imageprotect.com, successfully entering the digital copyright enforcement market and becoming Image Protect, Inc. The two companies were perfectly suited for each other.  On one hand, former Image Technology Labs brought an established image and data organization platform. On the other, Image Protect brought a rapidly expanding copyright-enforcement business model. Together the two companies formed as one to create a rapid growing, revenue generating copyright enforcement business for the protection of digital image assets. The merger was so successful in fact, that in less than 9 months (OTCMKTS: IMTL) reported $299,024 for Q3 revenue, representing a 338% increaseover the previous quarter in 2015. By the end of 2016, (OTCMKTS: IMTL)had opened copyright infringements in 13 countries worldwide while processing an  upload of over 50 million images for protection. The Company has even executed exclusive agreements with six of the top photo producers in the world.

How is (OTCMKTS: IMTL) achieving such success in so little time? The answer is simple, really; the demand for this copyright is astounding when fully realized. Let’s start with the digital photography market as a whole. The digital photography market is $82.6 billion USD annually* and it is estimated that 8 out of every 10 images on commercial websites are stolen, depriving copyright owners of billions of dollars.

This market is broken up into two distinct categories. Industry Giants such as Facebook, Inc. (NASDAQ: FB) - who purchased Instagram for $1 billion in cash and stock, Twitter, Inc. (NYSE:TWTR), and Adobe Systems (NASDAQ: ADBE), serve as the distribution channels. The other half are the marketplace, which include giants such as Shutterstock, Inc. (NYSE: SSTK) and Shutterfly, Inc (NASDAQ: SFLY), with market caps of $1.91 billion and $1.78 billion respectively, represent the digital copyright clients. But don’t let these industry giants steal all of your attention. The $82.6 billion digital photography market is made up by amateur artists as well.

With the advent of digital cameras and smartphones, taking photographs worthy of the marketplace is easier and anyone can do it. Professional photography is not limited to professionals any longer. Professional photography can now be performed by anyone with a smartphone. In today’s age, a countless number of amateur photographers are selling their works on their own websites, contributing to this lucrative industry.

But behind all of the financial success of the digital photography marketplace, is an unaddressed problem; Copyright Infringement. (OTCMKTS: IMTL) is providing micro-cap investors the opportunity of investing in this untapped pool of economic opportunity. IMTL has grown from an incubation concept to an image enterprise with over 4 million images in its portfolio for copyright and infringement enforcement. By 2018, the industry potential shows that (OTCMKTS:IMTL) could be monitoring over 40 million images and protecting 6 million members. If the Company takes a mere 1% of these images and initiates 400,000 total potential infringements, it would generating $28,864,321 in potential revenue. With this being said, Image Protect Inc. (OTCMKTS:IMTL) is one to keep a close eye on.

* www.transparencymarketresearch.com/digital-photography-market.html

Home  Stock Market  OBMP Receives Approval for Phase 2 Clinical Trial of Prostate Cancer Vaccine Technology

OBMP Receives Approval For Phase 2 Clinical Trial Of Prostate Cancer Vaccine Technology

5:59:00 PM

On January 18th, 2017, (OTCMKTS:OBMP) OncBioMune Pharmaceutical, Inc, announced the receipt of acknowledgement and authorization for the Phase 2 clinical trial of the Company's proprietary vaccine technology, ProscaVax; further positioning the Company in $7.1 billion prostate cancer treatment market. ProscaVax, the Company's leading product, uses similar techniques developed for the treatment of breast cancer patients - by means of stimulating the immune system to attack its own cancer cells. ProscaVax works as a protein therapeutic cancer vaccine, which combines prostate-specific antigen PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to stimulate the patient's immune system to selectively destroy cancerous tumors without damaging healthy cells. The clinical study is being sponsored by OncBioMune Mexico S.A. de C.V., a joint venture between the Company and its planned acquisition target, Vitel Laboratorios S.A. de C.V., and being conducted at HSH IMSS, which is considered the foremost government hospital in Mexico.

This authorization comes as a tremendous vote of confidence for OncBioMune. The Company currently trades at $0.20, much cheaper than other biopharma companies in the prostate cancer market such as (NASDAQ:SGEN) Seattle Genetics, (NASDAQ:INO) Inovio Pharmaceuticals, and (NASDAQ:NYMX) Nymox Pharmaceutical Corporation. OncBioMune has a market cap of just $7.9 million, less than other companies targeting intellectual properties for prostate cancer such as (NYSE:LLY) Eli Lilly and Co and (NYSE:PFE) Pfizer Inc. 

                               

Reported on August 8th, 2016, The latest data from the Phase 1 trial of ProscaVax further reinforced the safety and benefit of the novel cancer vaccine. Among the 16 patients enrolled in the Phase 1a trial, no serious adverse events have been reported. Additional preliminary data from the trial shows ProscaVax to provide a meaningful clinical benefit to prostate cancer patients. This data includes:

• - 15 of 20 patients in the Phase 1a portion of the trial have received at least one vaccine injection and 14 patients have received all 6 vaccines
• - None of the 15 patients who have had at least one vaccine have had a dose limiting adverse event (DLAE)
• - None of the 14 patients who have received all 6 vaccines in the Phase 1a have had a DLAE
• - 9 of the 12 patients (75%) who have received 6 vaccines have had increased immune responses to PSA as determined with a LBA (lymphocyte blastogenesis assay)
• - 9 of 11 patients (82%) at 31 weeks post first vaccine have had an increased immune response to PSA as determined with a LBA
• - Three of the 14 patients who have received all 6 vaccines have experienced disease progression (one radiological, two PSA)

OncBioMune Pharmaceuticals was founded by the two men behind the first patented autologous breast cancer vaccine, Dr. Jonathan Head and Dr. Robert Elliott. The Company is leveraging technology that has been shown in hundreds of patients to be safe. ProscaVax aims to address the 200,000 patients diagnosed with prostate cancer annually. 

• OncBioMune on Facebook
• OncBioMune on Twitter
• OncBioMune on LinkedIn
• OncBioMune on SlideShare

TagsBIOPHARMACEUTICALNASDAQOTC STOCKSSTOCK MARKET

• FACEBOOK
• TWITTER
• GOOGLE+
• LINKEDIN
• TUMBLR
• PINTEREST

Previous PostASTI Ascent Solar Clinches Major Contract - Soars +42%Next PostOBMP Receives Approval for Phase 2 Clinical Trial of Prostate Cancer Vaccine Technology

RELATED ARTICLES

OBMP Receives Approval for Phase 2 Clinical Trial of Prostate Cancer Vaccine Technology

$AMD FORGET ALL OPINIONS OVER-SOLD AMD = BUY! BUY

$AMD FORGET ALL OPINIONS & UNDERSTAND that an OVER-SOLD AMD = BUY! BUY growth stocks when OVER SOLD!

Tesla rival Faraday Future admits cash is tight - January 2017

TRENDING:

• CES 2017

• Apple Watch 2

• iPhone 7

• Galaxy S7 vs iPhone 6S

• Google Pixel

• Galaxy S7

Home / 

News / Internet News / Tesla rival Faraday Future admits cash is tight

"Tesla rival Faraday Future admits cash is tight"

- January 2017

Read Comments

0:00

/

1:38

Faraday Future, a company that's looking to take on Tesla at the luxury end of the smart car market, has admitted that it had to put building its ambitious $1 billion factory on hold to finance its presence at CES this year.

When Faraday Future turned heads at CES 2016 with the launch of its concept car, it always seemed like an optimistic project that would need to overcome an awful lot of hurdles. Cashflow, it seems, is one of those major issues, according to Faraday's senior vice president of R&D Nick Sampson.

In an interview with the BBC, Sampson confirmed that work on the factory in which to build the vehicles had been halted to fund CES, but that it's only a temporary hold.

"The challenge of building a new company is that it’s not just doing the engineering and R&D work, we’ve got manufacturing to keep aligned, we’ve also got the whole sales and marketing, branding and imaging," Sampson said.

At CES 2017, the company showed off an altogether more realistic electric car design, dubbed the FF91, which the company claims goes from 0-60 in just under 2.5 seconds. It's also got some self-parking smarts, and is expected to offer other autonomous functions in the future.

Faraday Future says it'll start selling the FF91 in 2018, and you can put down a $5,000 (£4,106) refundable deposit, but only if you're based in the US, Canada or China for now.

Related: Look out Tesla, Faraday Future just launched a new super-fast electric car

Watch The Refresh: The best tech gossip and reviews every week

0:00

/

2:46

Would you be interested in reserving the FF91? Think electric cars are still too range-limited? Let us know in the comments below!

Read more at http://www.trustedreviews.com/news/tesla-rival-faraday-future-admits-cash-is-tight#ydLMmFzKzcyO6DuZ.99